PATENT
Docket No. 740481-42

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:	)		400
Robert M. LORENCE et al	)	Group Art Unit:	I S THE REPORTS OF THE PROPERTY OF THE PROPERT
Serial No. 10/700,143	)	Examiner: .	CENTERIU
Filed: November 3, 2003	)		TELAT
For: TREATING CARCINOID NEOPLASMS WITH THERAPEUTIC VIRUSES	)		

CERTIFICATE OF MAILING OR TRANSMISSION
[37 CFR 1.8(a)]

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on November 8, 2004.

Signature:

Name:

Stuart J. Friedman

## **SUBMISSION UNDER 37 CFR 1.99**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

11/10/2004 SDENBOB1 00000076 10700143

01 FC:1806 02 FC:1460

180.00 OP 130.00 OP

Sir:

The following publications are submitted for consideration by the Patent and Trademark Office in connection with the above-captioned application:

Attenuated Veterinary Virus Vaccines for the Treatment of Colorectal Cancer, as Biological Response Modifiers; L. K. Csatary et al; 2d International Conference on Gastrointestinal Cancer; August 27-September 1, 1989.

<u>Treatment of Malignant Tumors with Attenuated Newcastle Disease Virus Vaccine</u> (Phase II Trial); L. Csatary et al; Update in Medicine, Surgery and Basic Science 1992; October 25-October 30, 1992.

Page 2

Attenuated Veterinary Virus Vaccine for the Treatment of Cancer; Laszlo K. Csatary et al; Cancer Detection and Prevention, 17(6): 619-627 (1993)

<u>Use of Newcastle Disease Virus Vaccine (NMTH-68/H) in a Patient With High-Grade Glioblastoma</u>; JAMA, Volume 281; May 5, 1999

Beneficial Treatment of Patients with Advanced Cancer Using a Newcastle Disease Virus Vaccine (MTH-68/H); Laszlo K. Csatary et al; Anticancer Research 19: 635-638 (1999)

Induction of Apoptosis by a Newcastle Disease Virus Vaccine (MTH-68/H) in PC12 Rat Phaeochromocytoma Cells; Z. Fabian et al; Anticancer Research 21: 125-136 (2001)

Pursuant to 37 CFR 1.99 (b)(1) submitter submits the fee (\$180.00) set forth in 37 CFR 1.17(p). Submitter notes that this submission is made more than two months after publication but prior to the mailing of a notice of allowance. The publications submitted herewith could not have been submitted earlier and, therefore, the processing fee set forth in 37 CFR 1.17(i) (\$130.00) is also enclosed for a total fee submission of \$310.00.

Respectfully submitted,

Stuart J. Priedman

Registration No. 24,312

Law Offices of Stuart J. Friedman 28930 Ridge Road Mt. Airy, MD 21771

Telephone: (301) 829-1003 Facsimile: (301) 829-4107



## CERTIFICATE OF SERVICE



This is to certify that a copy of the foregoing SUBMISSION UNDER 37 CFR 1.99 was served upon the applicant in accordance with 37 CFR 1.248 by mailing this 8<sup>th</sup> day of November, 2004, via first class mail, postage prepaid, to:

Lewis J. Kreisler Legal Department Wellstat Biologics Corporation 930 Clopper Road Gaithersburg, MD 20878

Stuart J. Friedman